

## Special Issue

# Advances in Radiotherapy for Head and Neck Cancer

### Message from the Guest Editor

Radio(chemo)therapy is a standard of care, both in primary and adjuvant settings, in the treatment of head and neck cancer. Efficacy improvements mainly originate from the introduction of technical advances, altered fractionation regimens, new concomitant administration of targeted drugs, and integration of molecular imaging in target volume delineation. The aim of this Special Issue is to present a series of original (pre)clinical trials/translational studies/review articles that will highlight the progress that has been made in the management of head and neck cancer. The topics of interest include, but are not limited to, the following: chemoradiotherapy; radioimmunotherapy; hypoxia and radiotherapy; stereotactic radiotherapy; patient-reported outcome and radiotherapy; de-escalation strategies; proton therapy; flash therapy; follow-up strategies; biomarker and patient stratification.

### Guest Editor

Dr. Francesca De Felice

Department of Radiotherapy, Policlinico Umberto I, Sapienza University of Rome, 00168 Rome, Italy

### Deadline for manuscript submissions

closed (25 October 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/124451](https://mdpi.com/si/124451)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)